fluorobenzenes has been researched along with Pulmonary Hypertension in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jasińska-Stroschein, M; Orszulak-Michalak, D; Owczarek, J; Wesołowska, A | 1 |
| Adachi, O; Fukushige, S; Horii, A; Kawamoto, S; Matsuo, S; Saiki, Y | 1 |
| Maeda, K; Ruel, M | 1 |
| Barreto, AC; Cícero, C; Lopes, AA; Maeda, NY; Soares, RP | 1 |
| Andresen, BT; Dellsperger, KC; DeMarco, VG; Ferrario, CM; Gutweiler, AA; Habibi, J; Johnson, MS; Ma, L; Schneider, RI; Sowers, JR; Whaley-Connell, AT | 1 |
| Guan, RJ; Li, XL; Wu, ZY; Xu, QH | 1 |
| Dai, G; Ma, P; Pei, Y; Wang, X; Xu, Q; Yan, L; Zhang, W; Zhang, X; Zheng, P | 1 |
| Guan, RJ; Li, JJ; Li, XL | 1 |
| Ku, DD; Sun, X | 1 |
1 trial(s) available for fluorobenzenes and Pulmonary Hypertension
| Article | Year |
|---|---|
Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study.
Topics: Adolescent; Adult; Biomarkers; Case-Control Studies; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Female; Fluorobenzenes; Heart Defects, Congenital; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Middle Aged; P-Selectin; Pyrimidines; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Tissue Plasminogen Activator; von Willebrand Factor; Young Adult | 2008 |
8 other study(ies) available for fluorobenzenes and Pulmonary Hypertension
| Article | Year |
|---|---|
Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Biomarkers; Cholesterol, HDL; Disease Models, Animal; Drug Therapy, Combination; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Natriuretic Peptide, Brain; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Pyrimidines; Rats, Wistar; Rosuvastatin Calcium; Sildenafil Citrate; Sulfonamides; Time Factors; Vascular Endothelial Growth Factor A; Vascular Remodeling; Vasodilator Agents; Ventricular Function, Right; Ventricular Pressure | 2014 |
Single-dose rosuvastatin ameliorates lung ischemia-reperfusion injury via upregulation of endothelial nitric oxide synthase and inhibition of macrophage infiltration in rats with pulmonary hypertension.
Topics: Animals; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Disease Models, Animal; Endothelium, Vascular; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Lung; Lung Injury; Macrophages; Male; Mevalonic Acid; Monocrotaline; Nitric Oxide Synthase Type III; Oxygen; Phosphorylation; Pulmonary Edema; Pyrimidines; Rats, Sprague-Dawley; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides; Up-Regulation | 2015 |
Prevention of ischemia-reperfusion injury in cardiac surgery: therapeutic strategies targeting signaling pathways.
Topics: Animals; Anti-Inflammatory Agents; Endothelium, Vascular; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Lung; Lung Injury; Macrophages; Male; Nitric Oxide Synthase Type III; Pyrimidines; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides | 2015 |
Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat.
Topics: Angiotensinogen; Animals; Fluorobenzenes; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Left Ventricular; Hypertrophy, Right Ventricular; Magnetic Resonance Imaging; Male; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Peptidyl-Dipeptidase A; Pulmonary Artery; Pyrimidines; rac1 GTP-Binding Protein; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Angiotensin, Type 1; Rosuvastatin Calcium; Sulfonamides; Ventricular Function, Left; Ventricular Function, Right | 2009 |
[Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats].
Topics: Animals; Cell Proliferation; Endothelial Cells; Familial Primary Pulmonary Hypertension; Fluorobenzenes; Hypertension, Pulmonary; Hypolipidemic Agents; Male; Monocrotaline; Myocytes, Smooth Muscle; Nitric Oxide Synthase Type III; Proliferating Cell Nuclear Antigen; Pyrimidines; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Rosuvastatin Calcium; Sulfonamides | 2011 |
Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism.
Topics: Amidohydrolases; Animals; Arginine; Biomarkers; Body Weight; Fluorobenzenes; Gene Expression Regulation, Enzymologic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Heart; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Nitric Oxide Synthase Type III; Organ Size; Protein-Arginine N-Methyltransferases; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; Ventricular Dysfunction, Right | 2011 |
Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Fluorobenzenes; Gene Expression Regulation, Enzymologic; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Nitric Oxide Synthase Type III; Proliferating Cell Nuclear Antigen; Pulmonary Artery; Pyrimidines; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2012 |
Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats.
Topics: Animals; Blood Pressure; Blotting, Western; Body Weight; Coronary Disease; Endothelium, Vascular; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Nitric Oxide; Organ Size; Poisons; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Sulfonamides | 2008 |